Literature DB >> 10837074

Multiple roles for the major histocompatibility complex class I- related receptor FcRn.

V Ghetie1, E S Ward.   

Abstract

Multiple functions have recently been identified for the neonatal Fc receptor FcRn. In addition, a human homolog of the rodent forms of FcRn has been identified and characterized. This major histocompatibility complex class I-related receptor plays a role in the passive delivery of immunoglobulin (Ig)Gs from mother to young and the regulation of serum IgG levels. In addition, FcRn expression in tissues such as liver, mammary gland, and adult intestine suggests that it may modulate IgG transport at these sites. These diverse functions are apparently brought about by the ability of FcRn to bind IgGs and transport them within and across cells. However, the molecular details as to how FcRn traffics within cells have yet to be fully understood, although in vitro systems have been developed for this purpose. The molecular nature of the FcRn-IgG interaction has been studied extensively and encompasses residues located at the CH2-CH3 domain interface of the Fc region of IgG. These Fc amino acids are highly conserved in rodents and man and interact with residues primarily located on the alpha2 domain of FcRn. Thus, it is now possible to engineer IgGs with altered affinities for FcRn, and this has relevance to the modulation of IgG serum half-life and maternofetal IgG transport for therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10837074     DOI: 10.1146/annurev.immunol.18.1.739

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  152 in total

1.  IgG transcytosis and recycling by FcRn expressed in MDCK cells reveals ligand-induced redistribution.

Authors:  T S Ramalingam; Scott A Detmer; W Lance Martin; Pamela J Bjorkman
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

Review 2.  In vivo immunogenetics: from MIC to RAET1 loci.

Authors:  Mirjana Radosavljevic; Seiamak Bahram
Journal:  Immunogenetics       Date:  2003-03-20       Impact factor: 2.846

Review 3.  Immunomodulatory action of intravenous immunoglobulin.

Authors:  W A C Sewell; S Jolles
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

Review 4.  Diversity and duplicity: human FCgamma receptors in host defense and autoimmunity.

Authors:  Robert P Kimberly; Jianming Wu; Andrew W Gibson; Kaihong Su; Hongwe Qin; Xiaoli Li; Jeffrey C Edberg
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 5.  Therapeutic strategies in common variable immunodeficiency.

Authors:  W A Carrock Sewell; Matthew Buckland; Stephen R A Jolles
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level.

Authors:  Raimund J Ober; Cruz Martinez; Xuming Lai; Jinchun Zhou; E Sally Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-16       Impact factor: 11.205

Review 7.  The role of sialic acid as a modulator of the anti-inflammatory activity of IgG.

Authors:  Sybille Böhm; Inessa Schwab; Anja Lux; Falk Nimmerjahn
Journal:  Semin Immunopathol       Date:  2012-03-22       Impact factor: 9.623

8.  Monoclonal antibodies directed against human FcRn and their applications.

Authors:  Gregory J Christianson; Victor Z Sun; Shreeram Akilesh; Emanuele Pesavento; Gabriele Proetzel; Derry C Roopenian
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

9.  JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8(+) T cells and pre-exposure neutralizing antibody.

Authors:  Maximilian Larena; Natalie A Prow; Roy A Hall; Nikolai Petrovsky; Mario Lobigs
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

10.  FcRn in the yolk sac endoderm of mouse is required for IgG transport to fetus.

Authors:  Jonghan Kim; Sudhasri Mohanty; Latha P Ganesan; Keding Hua; David Jarjoura; William L Hayton; John M Robinson; Clark L Anderson
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.